Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Effects of cannabis
Botanix Pharmaceuticals
Другие языки:

    Botanix Pharmaceuticals

    Подписчиков: 0, рейтинг: 0

    Botanix Pharmaceuticals Limited
    Type Listed Public Company
    ASX: BOT
    Industry Biotechnology
    Headquarters Perth, Western Australia, and Philadelphia, USA
    Area served
    		 Global
    Key people
    • Vince Ippolito, President and executive chairman
    • Matt Callahan, Founder and executive director
    • Dr Stewart Washer, Director
    • Dr Bill Bosch, Chief scientific officer and executive director
    • Danny Sharp, Non-executive director
    Products BTX 1503 | For the treatment of moderate to severe acne

    BTX 1702 | For the treatment of rosacea BTX 1204A | For the treatment of moderate atopic dermatitis

    BTX 1801 | For use in a variety of antimicrobial applications
    Website www.botanixpharma.com

    Botanix Pharmaceuticals is listed on the Australian Securities Exchange with the issue code BOT. The Company is headquartered in Perth, Western Australia and Philadelphia, USA. It is a clinical stage synthetic cannabinoid company, focusing on the compound Cannabidiol. The company has two separate development platforms, dermatology and antimicrobial. Botanix also has an exclusive license to use a proprietary drug delivery system Permetrex, for direct skin delivery of active pharmaceuticals which is utilised in all of their programs.

    Research

    Botanix Pharmaceuticals product pipeline currently includes four programs for treatment of serious skin diseases:

    Dermatology

    • BTX 1503, for the treatment of moderate to severe acne
    • BTX 1702, for the treatment of rosacea
    • BTX 1204A, for the treatment of moderate atopic dermatitis

    Antimicrobial

    • BTX 1801, for use in a variety of antimicrobial applications

    External links


    Новое сообщение